{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:35:35Z","timestamp":1792794935107,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.beem.2022.101658","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T14:07:36Z","timestamp":1649772456000},"page":"101658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Approach to patients with elevated low-density lipoprotein cholesterol levels"],"prefix":"10.1016","volume":"37","author":[{"given":"Kenneth R.","family":"Feingold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Chait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2022.101658_bib1","series-title":"Endotext","article-title":"Guidelines for the management of high blood cholesterol","author":"Grundy","year":"2019"},{"key":"10.1016\/j.beem.2022.101658_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A\u00a0century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.beem.2022.101658_bib3","series-title":"Endotext","article-title":"Familial hypercholesterolemia: genes and beyond","author":"Warden","year":"2021"},{"key":"10.1016\/j.beem.2022.101658_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101658_bib5","series-title":"Endotext","article-title":"Cholesterol lowering drugs","author":"Feingold","year":"2021"},{"key":"10.1016\/j.beem.2022.101658_bib6","series-title":"Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis","author":"Mensink","year":"2016"},{"key":"10.1016\/j.beem.2022.101658_bib7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.beem.2022.101658_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s11745-010-3393-4","article-title":"Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence","volume":"45","author":"Micha","year":"2010","journal-title":"Lipids"},{"key":"10.1016\/j.beem.2022.101658_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcn\/nqy273","article-title":"Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol","volume":"109","author":"Vincent","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.beem.2022.101658_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s11883-009-0063-1","article-title":"Dietary cholesterol and coronary artery disease: a systematic review","volume":"11","author":"Djousse","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.beem.2022.101658_bib11","series-title":"Endotext","article-title":"The effect of diet on cardiovascular disease and lipid and lipoprotein levels","author":"Feingold","year":"2021"},{"key":"10.1016\/j.beem.2022.101658_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol-lowering effects of dietary fiber: a meta-analysis","volume":"69","author":"Brown","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.beem.2022.101658_bib13","series-title":"Endotext","article-title":"Medication induced changes in lipid and lipoproteins","author":"Herink","year":"2018"},{"key":"10.1016\/j.beem.2022.101658_bib14","series-title":"Endotext","article-title":"Genetics and dyslipidemia","author":"Patni","year":"2020"},{"key":"10.1016\/j.beem.2022.101658_bib15","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2022.101658_bib17","series-title":"Endotext","article-title":"Is atherosclerosis a pediatric disease?","author":"Wilson","year":"2020"},{"key":"10.1016\/j.beem.2022.101658_bib18","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101658_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2019.03.529","article-title":"Associations of blood pressure and cholesterol levels during young adulthood with later cardiovascular events","volume":"74","author":"Zhang","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2022.101658_bib21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.beem.2022.101658_bib22","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2022.101658_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2022.101658_bib24","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2022.101658_bib25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2022.101658_bib26","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101658_bib27","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101658_bib28","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101658_bib29","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/jamacardio.2017.3944","article-title":"Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.beem.2022.101658_bib30","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2022.101658_bib31","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101658_bib32","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2022.101658_bib33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the ODYSSEY OUTCOMES trial","volume":"143","author":"Schwartz","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib34","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2022.101658_bib35","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","article-title":"Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2022.101658_bib36","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.116.024436","article-title":"Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting","volume":"135","author":"Natarajan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101658_bib38","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/eurheartj\/ehw377","article-title":"The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial","volume":"37","author":"Eisen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2022.101658_bib39","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2022.101658_bib41","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2022.101658_bib42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.119.044434","article-title":"Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial","volume":"141","author":"Damask","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib43","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCULATIONAHA.119.043805","article-title":"Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER trial","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib46","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2022.101658_bib47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1161\/CIRCULATIONAHA.108.800235","volume":"119","author":"Berry","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib48","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.jacc.2021.08.065","article-title":"Cost-effectiveness of lipid-lowering treatments in young adults","volume":"78","author":"Kohli-Lynch","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2022.101658_bib49","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2022.101658_bib50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beem.2022.101658_bib51","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22000458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:52Z","timestamp":1761497932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22000458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1521690X22000458"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101658","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to patients with elevated low-density lipoprotein cholesterol levels","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101658"}}